𝔖 Bobbio Scriptorium
✦   LIBER   ✦

6561 POSTER Updated Survival and Safety Data From RADIANT-3 – a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET)

✍ Scribed by Lombard-Bohas, C.; Van Cutsem, E.; Capdevila, J.; de Vries, E.G.E.; Tomassetti, P.; Lincy, J.; Winkler, R.E.; Hobday, T.; Pommier, R.; Yao, J.C.


Book ID
122921324
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
43 KB
Volume
47
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES